Full-Time

Director – HIV Treatment Marketing

Posted on 4/28/2025

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical company developing innovative medicines

Compensation Overview

$226.2k - $292.7k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

Company Historically Provides H1B Sponsorship

San Mateo, CA, USA

Category
General Marketing
Growth Marketing
Growth & Marketing
Required Skills
Social Media
Requirements
  • Bachelor's Degree and 10 years of experience
  • OR
  • Master's Degree and 8 years of experience
  • Direct-to-Patient Marketing experience required
Responsibilities
  • Develop effective patient retention and engagement strategies aimed at optimizing brand performance and addressing unmet needs in the HIV patient journey.
  • Develop local / regional market strategic plans, inclusive of communication strategies, community engagement opportunities, patient activation, and media.
  • Partner with the Franchise Community Engagement lead responsible for the execution of local market plans
  • Leads branded AHCP content strategy and resource creation for community liaison team
  • Build out market growth initiatives to drive re-engagement in care
  • Lead unbranded DTP/DTC strategy, campaign, and messaging execution across website, digital and print assets, and patient resources.
  • Develop and execute the unbranded media plan, identify effective media channels and partners (e.g., digital, social media, print, video) to engage targeted HIV populations.
  • Conference Oversight: Oversee brand strategy and booth/activity execution for HIV treatment DTP conferences.
  • Cross-Functional Collaboration: Partner with the HIV Franchise, Public Affairs, and Community Field Teams to ensure aligned efforts for patient retention and market growth.
  • Culturally Competent Communication: Create effective, culturally relevant content and messaging to educate consumers, patients, and healthcare providers (AHCPs) and support adherence.
  • Agency Management: Manage agency relationships to ensure performance and collaboration meet business needs.
  • Budget and Resource Management: Oversee budgets and resource allocation to ensure efficient and impactful deployment of resources.
  • Compliance: Ensure alignment with all relevant laws, regulations, and policies.
Desired Qualifications
  • 8+ years of marketing experience, primarily within the biopharmaceutical or pharmaceutical industry.
  • MBA preferred; bachelor’s degree in marketing or a related field required.
  • Extensive understanding of pharmaceutical regulatory requirements and their impact on marketing material development.
  • HIV-specific experience highly desirable.
  • Prior advertising, digital, or communications agency experience is a plus.

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and manufacturing practices. The company's goal is to enhance health equity and access to care, working with communities globally to ensure that its medicines reach those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead's $32 billion U.S. investment will create 3,000 jobs by 2028.
  • Lenacapavir's long-acting formulation offers potential for improved HIV patient adherence.
  • Gilead's sustainability initiatives enhance corporate social responsibility and patient engagement.

What critics are saying

  • $202 million settlement may impact Gilead's financial stability and reputation.
  • Layoffs among senior management could disrupt strategic decision-making and efficiency.
  • Increased competition from AI-driven drug discovery companies poses a market challenge.

What makes Gilead Sciences unique

  • Gilead focuses on innovative medicines for unmet medical needs like HIV/AIDS and liver diseases.
  • The company invests heavily in R&D to maintain a robust pipeline of new treatments.
  • Gilead's partnerships enhance product offerings and expand market reach globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

Gilead Sciences
May 7th, 2025
Gilead U.S. Investment to Create $43 Billion in Value to U.S. Economy

Gilead to invest $32 billion in U.S. manufacturing and R&D through 2030 and create more than 3,000 direct and indirect jobs by 2028

Constantine Cannon
May 5th, 2025
Gilead Pays $202M to Settle False Claims Act Kickback Charges

On April 29, the Department of Justice (DOJ) announced that California-based pharmaceutical giant Gilead Sciences agreed to pay $202 million to settle charges of violating the False Claims Act and Anti-Kickback Statute.

Financial Modeling Prep
May 2nd, 2025
Amgen Inc. (NASDAQ:AMGN) Surpasses Earnings and Sales Estimates in Q1 2025

Amgen competes with other biotech giants like Gilead Sciences and Biogen.

SFist
Apr 2nd, 2025
April Fool's Day Around the Bay: Bob Lee's Family Has Sued His Convicted Killer Nima Momeni

Foster City-based HIV drug company Gilead Sciences is laying off nearly 150 people, and the job cuts are significant among senior members of the company's management.

Labiotech
Mar 27th, 2025
12 Ai Drug Discovery Companies You Should Know About

Newsletter Signup - Under Article / In Page"*" indicates required fields Artificial intelligence (AI) has taken the biotech industry by storm, allowing companies to speed up the drug discovery process while also making it more cost-effective. With so many companies in the industry now embracing the technology, we take a look at 12 AI drug discovery companies. The COVID-19 pandemic revealed AI to be an essential tool in helping to find treatments and vaccines with greater speed and precision. Since then, there have been several drug discovery breakthroughs for AI within the biopharma industry, from helping to quickly and efficiently discover a new antibiotic called abaucin to combat a multi-drug resistant bacteria, to fully discovering and designing a drug that has entered clinical trials. Here are 12 AI drug discovery companies currently making great strides with their technology. Anima Biotech Technology: mRNA biology modulators Disease areas: Immunology, oncology and neuroscienceRecent news: Announced promising preclinical data for lead pulmonary fibrosis candidate Anima Biotech’s AI drug discovery technology is built around its mRNA Lightning.AI platform, which images hundreds of cellular pathways in both healthy and diseased cells to train disease-specific AI models, making use of neural networks to help these models distinguish between healthy and diseased cells and identify dysregulated pathways. These pathways are subsequently analyzed to uncover novel targets backed by experimental validation. Anima currently has 20 preclinical candidates being evaluated for immunology, oncology, and neuroscience indications, with its most advanced candidate indicated for the treatment of lung fibrosis. The company announced in February 2024 that this candidate had shown promising preclinical results and could open up new avenues for treating patients with idiopathic pulmonary fibrosis. The AI drug discovery company also has ongoing collaborations with several pharma giants. After initially partnering with Eli Lilly in 2018 and Takeda in 2021, its most recent partnership was formed with AbbVie in 2023 for the discovery and development of mRNA biology modulators against oncology and immunology targets. Atomwise Technology: TYK2 inhibitor  Disease area: Autoimmune and autoinflammatory diseasesRecent news: Published results showcasing AtomNet’s ability for drug discoveryAtomwise is leveraging the power of AI in an attempt to revolutionize small molecule drug discovery

INACTIVE